圣马力诺将其Carragelos的生意卖给Unitedher制药公司,价值高达2 000万欧元。 Marinomed sells its Carragelose business to Unither Pharmaceuticals for up to €20 million.

Marinomed Biotech AG 已同意以高达 2000 万欧元的价格将其 Carragelose 业务出售给法国制药公司 Unither Pharmaceuticals。 Marinomed Biotech AG has agreed to sell its Carragelose business to Unither Pharmaceuticals, a French pharmaceutical company, for up to €20 million in payments. 此举使圣马力诺得以将重点放在其他业务领域,并支持其重组计划。 This move allows Marinomed to focus on other business areas and supports its restructuring plan. 这项以重组批准和股东同意为条件的交易旨在加强Unither在制药部门的地位。 The deal, contingent on restructuring approval and shareholder consent, aims to strengthen Unither's position in the pharmaceutical sector.